Patients' Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.

Bidur BanjaraNabin PoudelKimberly B Garza Salisa C Westrick Heather P WhitleyDavid ReddenSurachat Ngorsuraches

Published in: Patient preference and adherence (2022)

T2DM patients placed different preference weights or importance across SGLT-2i and GLP-1 RA attributes. Preference heterogeneity was found among patients with different ages and numbers of comorbidities.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
patient reported outcomes
metabolic syndrome
patient reported
glycemic control